Research Institute
You are here: Home » R&D » Research Institute

Cutting-Edge Research Institute of Loncom Pharma

The research institute occupies an area of more than 10,000 square meters and possesses over 200 high-performance liquid chromatography instruments, including ‘Waters’, ‘Hitachi’, and ‘Shimadzu’, as well as gas chromatographs. It also boasts several hundred sets of precision equipment, such as the Alltech evaporative light scattering detector, ultraviolet spectrophotometers, diode array detectors, laser particle size analyzers, and fully automated dissolution testers. Furthermore, it is equipped with various pilot-scale devices for different dosage forms, including capsules, tablets, microspheres, and lyophilized products.
Research Institute of Mirabegron, Lacosamide, Dapoxetine HCl supplier

Research Institute

By the end of 2022, the research institute has a team of 509 pharmaceutical researchers, including 212 with master's and doctoral degrees. Over 81.3% of the team members hold undergraduate degrees or higher, with more than 30% being senior researchers. There are over 60 individuals with over 10 years of research and development experience. This team represents a high-quality workforce well-suited for pharmaceutical research and development. The institute has also engaged more than ten renowned experts and professors in the industry as advisors. These advisors come from institutions such as the China Pharmaceutical University, Shanghai Institute of Organic Chemistry, Shenyang Pharmaceutical University, and Stanford University in the United States, forming an advisory team of more than 20 experts to support the company's project initiation, investment, and development.

The institute offers an one-stop solution in areas such as project initiation, pharmacy, bio-equivalence, clinical trials, registration application, and post-market evaluation. Its core business includes research and development of new drugs/generic drugs, bio-equivalence assessment, biological sample testing, packaging material compatibility studies, registration application, and post-market adverse reaction monitoring.
With a complete end-to-end R&D capability and system, the research institute adheres to the "Drug Design For X" (DDFXBN) R&D design theory. It has established efficient operational mechanisms and a scientific R&D system in accordance with international standards.
R&D about Lacosamide, Dapoxetine HCl manufacturer
Functional departments include project management, quality management, knowledge management, drug synthesis, drug formulation, drug analysis, clinical research, human resources, and marketing department. The institute has established state-of-the-art pharmaceutical pilot facilities and high-end GMP production bases for active pharmaceutical ingredients & formulations, Moreover, It creates an integrated one- stop R&D system and platform that covers the entire industry chain from pharmacy to bio-equivalence, from small-scale testing to production (project consultation, product planning, pharmacy technical services, BE trials, registration application, market approval system construction, contract manufacturing, and training).
As a globally aligned new drug R&D platform, the institute consistently adheres to the highest ICH standards. It is one of the first in the industry to introduce the world's most advanced ‘Empower 3’ database management system. In terms of quality control, project management, knowledge management, laboratory informatization, and more, it has achieved industry-leading levels, ensuring the authenticity, security, and compliance of R&D data. The institute has introduced an advanced Integrated Product Development (IPD) process management system and fully implemented information management. It has developed a comprehensive set of regulations, processes, and templates related to project R&D and established an end-to-end process system, which ensures that project milestones and key milestones are achieved on time and effectively.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.



Copyright © 2023 Shandong Loncom Pharmaceutical Co., Ltd. All Rights Reserved. Sitemap | Privacy Policy
Supported by
Contact Us